DD Is Not Just The Last Article Written on KERX, It Is Knowing Everything About The Co. and This Article Explains Why KERX Will be a Biotech Blockbuster: read
Keryx: A Small Biotech With Many Catalysts
Updated 6/ 10/13 By: George RHO
Considering Zerenex's efficacy, safety, and administration advantages, versus the three main rivals in the market, as well as its unique ability to provide iron benefits, Keryx's ferric citrate has the potential to become the leading phosphate binder in the world. We believe the shares still have considerable upside potential, to be realized in the quarters and years ahead.
Extreme Undervalued. Cheaper Than The Secondary !!
load up because next time you look it's in the mid- $20's and I kick myself for not getting in. This time I am in.
CNBC "Facebook Catching Up to Google "
Thursday, 30 May 2013 |
are there any higher? Thanks